SUPN biotech catalysts & pipeline

SUPERNUS PHARMACEUTICALS INC · Data as of 2026-09-08

Upcoming catalysts

apomorphine hydrochloride — NDA/BLA submission

Q3 2026

The Company remains on-track to submit a regulatory filing to the U.S. Food and Drug Administration (FDA) for a second supplier for ONAPGO in the third quarter of 2026, with potential FDA approval by mid-year 2027.

Source filing

apomorphine hydrochloride — PDUFA

Mid 2027

The Company remains on-track to submit a regulatory filing to the FDA for a second supplier for ONAPGO in the third quarter of 2026, with potential FDA approval by mid-year 2027.

Source filing

apomorphine hydrochloride — Regulatory decision

Mid 2027

The Company remains on-track to submit a regulatory filing to the U.S. Food and Drug Administration (FDA) for a second supplier for ONAPGO in the third quarter of 2026, with potential FDA approval by mid-year 2027.

Source filing

Explore the free biotech catalyst calendar